INS.L Regulatory News (INS)

20 February 2012

Instem plc

("Instem", or the "Company")

Notice of Final Results

Instem plc (AIM: INS.L), a leading provider of IT applications to the global early development healthcare market, will be announcing its final results for the year ended 31 December 2011 on 28 March 2012.

Management will be hosting a presentation for analysts on the day of results at 11am at the offices of Newgate Threadneedle: 3rd Floor Aldermary House, 10-15 Queen Street, London, EC4N 1TX.

Analysts who wish to attend the presentation should register their interest with Fiona Conroy, contactable at f.conroy@newgatethreadneedle.com or 020 7653 9847.

For further information, please contact:

About Instem plc

Instem (AIM:INS.L) is a leading supplier of IT solutions to the early development healthcare market. Instem's pre-clinical study management solutions accelerate drug and chemical development by increasing productivity, automating processes and enhancing practices that lead to safer and more effective drugs.

In March 2011 Instem acquired BioWisdom Limited, a leading provider of software solutions for extracting intelligence from R&D related healthcare data and subsequently renamed the business Instem Scientific. The acquisition broadened and strengthened Instem's Centrus™ product suite, accelerating the product development roadmap.

Instem has over 130 customers in North America, Europe, China, India and Japan, including sixteen of the top twenty pharmaceutical and biotech companies such as GlaxoSmithKline and AstraZeneca. The Company employs over 110 people in six offices in the U.S, UK, and China; with additional resource locations in India and a full service distributor in Japan. It is estimated that approximately half of the world's pre-clinical drug safety data has been collected over the last 20 years via Instem software.

To learn more about Instem please visit the Company's website, www.instem.com, or its investor centre http://investors.instem.com/.